EMFLAZA® (deflazacort) is NOW indicated for the treatment of Duchenne muscular dystrophy in patients 2 YEARS OF AGE AND OLDER.

Treating Duchenne with corticosteroids

Corticosteroid therapy, along with other improvements in Duchenne management, have positively impacted the natural history of the disease and delay disease milestones.1 Treatment with corticosteroids has been shown to increase muscle strength in children affected by Duchenne.

The American Academy of Neurology (AAN), and the U.S. Centers for Disease Control and Prevention (CDC) recommend corticosteroids as part of Duchenne treatment.2,3


Icon of AAN

American Academy of Neurology
(AAN) 2016

AAN guidelines recommend corticosteroids as an intervention for patients affected by Duchenne muscular dystrophy that may be used to improve muscle strength and may be used to improve motor function.3

Icon of Centers for Disease Control

U.S. Centers for Disease Control and Prevention (CDC) 2010

A panel of experts convened by the CDC, in collaboration with multiple organizations, recommend that the initiation of corticosteroids must be an individual decision, based on functional state, age, and preexisting risk factors for adverse side effects.

This panel was reconvened in 2018 to update their earlier recommendations. The update, published in the Lancet Neurology in 2018, confirmed upon the 2010 recommendations.2

Icon of check mark

When to start corticosteroids

1. Bushby K, Connor E. Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig (Lond). 2011;1(9):1217-1235. 2. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251-267. 3. Gloss D, Moxley RT, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2016;86:465-472.